US · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
Panacea Life Sciences Holdings, Inc. PLSH
10 fiscal years on record · USD · FY2023 reported
SEC FILINGS ONLY
Revenue · FY2023
$2.4M
▲ 46.6% vs FY2022
EPS · FY23
$-0.48
Dividend / sh · FY23
—
Payout · FY23
—
ROE · FY23
—
Net margin · FY23
-336.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 2.4M
Revenue, FY2023 · full 10-year series below
Revenue
Net income
The company lost 336 cents on every revenue dollar this year.
Per share
USD -0.48
Diluted EPS, FY2023
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2023
ROE
Operating margin-232.5%
Net margin-336.1%
Return on assets-42.8%
Returned to shareholders
—
returned in FY2023 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−35.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.02B
Shares outstanding, FY2023
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 18.0M
total assets, end of FY2023
Total assetsUSD 18.0M
EquityUSD -8.3M
CashUSD 100,922.00
Current ratio0.24×
Equity funds -46% of total assets.
History
10 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
·
·
·
·
·
0.0
0.0
0.0
0.0
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.48
−0.62
−0.27
−0.31
−0.30
−0.91
−0.91
−0.08
−0.70
−0.02
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
ROE %
·
−368.8
−69.3
−56.1
−235.3
·
·
−227.9
·
−648.0
Shares out B
0.02
0.01
0.01
0.02
0.04
0.01
0.00
0.03
0.00
0.02
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
36 of 36
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed